Adipotide (FTTP) Peptide: Research in Targeted Adipose Tissue Vasculature
May 8, 2026 Adipotide, also known as FTTP (Fat Targeted Pro-apoptotic Peptide), is an experimental peptidomimetic research agent designed to target and eliminate white adipose tissue. Research indicates that Adipotide operates through a unique mechanism…
AICAR Peptide: Research in Metabolic Activation and Cellular Energy Homeostasis
May 8, 2026 AICAR (Aminoimidazole carboxamide ribonucleotide) is a synthetic analog of adenosine monophosphate (AMP) that serves as a potent metabolic regulator. Research indicates that AICAR is a cell-permeable activator of AMP-activated protein kinase…
AOD9604 Peptide: Research in Lipolysis and Cartilage Regeneration
May 8, 2026 AOD9604 (Advanced Obesity Drug) is a synthetic peptide fragment derived from the C-terminal end of human growth hormone (hGH), specifically encompassing amino acids 177-191 with an added tyrosine at the N-terminal to stabilize the molecule.…
Retatrutide Peptide: Research in Triple-Agonist Metabolic Regulation
May 8, 2026 Retatrutide (also known as LY3437943) is an experimental synthetic peptide that represents the frontier of metabolic research. It is a “triple agonist” (tri-agonist) designed to target three distinct hormone receptors:…
Cagrilintide Peptide: Research in Dual-Pathway Appetite Suppression and Metabolic Synergy
May 11, 2026 Cagrilintide is an experimental long-acting analogue of the human hormone Amylin. Research indicates that Cagrilintide acts as a non-selective agonist of the amylin receptors (AMYR) and the calcitonin receptors (CTR). While its primary…
CagriSema: Research in the Synergistic Agonism of GLP-1 and Amylin Pathways
May 11, 2026 CagriSema is a fixed-dose combination research compound consisting of two potent long-acting peptides: Cagrilintide and Semaglutide. Research indicates that CagriSema represents a breakthrough in multi-modal metabolic therapy, aiming to…
Tirzepatide Peptide: A Dual-Agonist Approach to Metabolic Research and Weight Regulation
Tirzepatide is a novel, synthetic peptide that research indicates is a first-of-its-kind dual agonist, synergistically combining the properties of Glucose-dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) receptor agonists.…